Kexing Biopharm Co Ltd
SSE:688136
Kexing Biopharm Co Ltd
SSE:688136
Price:
30.84
CNY
-1.56%
Market Closed
Market Cap:
¥6.2B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Kexing Biopharm Co Ltd
SSE:688136
|
CN |
|
T
|
Toshiba Corp
XBER:TSE1
|
JP |
Balance Sheet
Balance Sheet Decomposition
Kexing Biopharm Co Ltd
Kexing Biopharm Co Ltd
Balance Sheet Decomposition is not available for
Kexing Biopharm Co Ltd
Kexing Biopharm Co Ltd
Balance Sheet
Kexing Biopharm Co Ltd
Kexing Biopharm Co Ltd
Currency: CNY
| Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash & Cash Equivalents |
66
|
46
|
150
|
1 088
|
875
|
784
|
560
|
553
|
|
| Cash |
0
|
0
|
0
|
0
|
875
|
784
|
560
|
553
|
|
| Cash Equivalents |
66
|
46
|
150
|
1 088
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
215
|
285
|
357
|
413
|
391
|
395
|
349
|
584
|
|
| Accounts Receivables |
190
|
242
|
317
|
394
|
346
|
337
|
275
|
475
|
|
| Other Receivables |
25
|
43
|
40
|
20
|
45
|
57
|
74
|
109
|
|
| Inventory |
91
|
85
|
138
|
113
|
172
|
208
|
191
|
142
|
|
| Other Current Assets |
3
|
53
|
3
|
29
|
23
|
25
|
34
|
9
|
|
| Total Current Assets |
374
|
469
|
648
|
1 644
|
1 461
|
1 411
|
1 134
|
1 288
|
|
| PP&E Net |
311
|
324
|
460
|
656
|
1 000
|
1 159
|
1 214
|
1 178
|
|
| PP&E Gross |
311
|
324
|
460
|
656
|
1 000
|
1 159
|
1 214
|
1 178
|
|
| Accumulated Depreciation |
111
|
100
|
116
|
136
|
168
|
204
|
271
|
318
|
|
| Intangible Assets |
27
|
35
|
34
|
37
|
27
|
166
|
159
|
256
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
247
|
280
|
267
|
246
|
|
| Other Long-Term Assets |
31
|
26
|
38
|
30
|
94
|
142
|
258
|
194
|
|
| Total Assets |
743
N/A
|
854
+15%
|
1 180
+38%
|
2 367
+101%
|
2 829
+20%
|
3 159
+12%
|
3 031
-4%
|
3 162
+4%
|
|
| Liabilities | |||||||||
| Accounts Payable |
150
|
135
|
133
|
158
|
225
|
217
|
193
|
204
|
|
| Accrued Liabilities |
14
|
19
|
27
|
33
|
40
|
40
|
28
|
37
|
|
| Short-Term Debt |
90
|
68
|
176
|
205
|
276
|
171
|
125
|
281
|
|
| Current Portion of Long-Term Debt |
4
|
35
|
52
|
17
|
18
|
72
|
282
|
326
|
|
| Other Current Liabilities |
261
|
43
|
52
|
28
|
44
|
40
|
42
|
39
|
|
| Total Current Liabilities |
520
|
301
|
440
|
441
|
604
|
539
|
670
|
886
|
|
| Long-Term Debt |
11
|
59
|
43
|
94
|
307
|
804
|
714
|
626
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
7
|
9
|
11
|
7
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
3
|
5
|
4
|
|
| Other Liabilities |
0
|
0
|
0
|
2
|
1
|
1
|
5
|
3
|
|
| Total Liabilities |
531
N/A
|
360
-32%
|
484
+34%
|
537
+11%
|
918
+71%
|
1 350
+47%
|
1 405
+4%
|
1 527
+9%
|
|
| Equity | |||||||||
| Common Stock |
61
|
149
|
149
|
199
|
199
|
199
|
199
|
200
|
|
| Retained Earnings |
151
|
245
|
226
|
365
|
446
|
336
|
145
|
177
|
|
| Additional Paid In Capital |
0
|
100
|
321
|
1 266
|
1 266
|
1 274
|
1 282
|
1 288
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
31
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
212
N/A
|
495
+133%
|
696
+41%
|
1 830
+163%
|
1 911
+4%
|
1 808
-5%
|
1 626
-10%
|
1 635
+1%
|
|
| Total Liabilities & Equity |
743
N/A
|
854
+15%
|
1 180
+38%
|
2 367
+101%
|
2 829
+20%
|
3 159
+12%
|
3 031
-4%
|
3 162
+4%
|
|
| Shares Outstanding | |||||||||
| Common Shares Outstanding |
61
|
149
|
149
|
199
|
199
|
199
|
199
|
198
|
|
Switch to:
Switch to:
See Also
Discover More
